Cumulative proportion of cervical intraepithelial neoplasia 2+ and CIN3+ at 36 and 72 months by human papillomavirus status at baseline (95% CIs)
| 36 months | 72 months | ||||
|---|---|---|---|---|---|
| CIN2+ | CIN2+ | ||||
| HPV status | N | % | 95% CI | % | 95% CI |
| In total | 11 220 | 0.78 | 0.62 to 0.94 | 1.52 | 1.27 to 1.77 |
| HPV-negative | 10 821 | 0.28 | 0.20 to 0.40 | 0.77 | 0.58 to 0.96 |
| HPV-positive | 399 | 14.0 | 10.5 to 17.5 | 22.7 | 17.5 to 28.9 |
| HPV31/33/45 (not 16, not 18) | 152 | 9.2 | 4.6 to 13.8 | 16.3 | 8.4 to 24.2 |
| HPV18 (not 16) | 58 | 17.2 | 7.5 to 26.9 | 20.7 | 20.3 to 31.1 |
| HPV16 | 189 | 16.9 | 11.5 to 22.3 | 27.8 | 20.5 to 35.1 |
| CIN3+ | CIN3+ | ||||
|---|---|---|---|---|---|
| HPV status | N | % | 95% CI | % | 95% CI |
| In total | 11 220 | 0.67 | 0.51 to 0.83 | 1.27 | 1.04 to 1.51 |
| HPV-negative | 10 821 | 0.28 | 0.20 to 0.40 | 0.62 | 0.46 to 0.79 |
| HPV-positive | 399 | 11.3 | 8.2 to 14.5 | 19.7 | 14.7 to 24.7 |
| HPV31/33/45 (not 16, not 18) | 152 | 7.2 | 3.1 to 11.3 | 14.3 | 6.7 to 21.9 |
| HPV18 (not 16) | 58 | 12.1 | 3.7 to 20.5 | 17.2 | 7.5 to 26.9 |
| HPV16 | 189 | 14.3 | 9.3 to 19.3 | 24.1 | 17.0 to 31.2 |